Asymmetric dimethylarginine (ADMA): the silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule.
about
Characterization of C-Alkyl Amidines as Bioavailable Covalent Reversible Inhibitors of Human DDAH-1Serum methylarginines and spirometry-measured lung function in older adultsL-Arginine supplementation or arginase inhibition augments reflex cutaneous vasodilatation in aged human skin.[Thrombocytopathy and blood complications in uremia].Cerebral changes occurring in arginase and dimethylarginine dimethylaminohydrolase (DDAH) in a rat model of sleeping sicknessDimethylarginine metabolism during acute and chronic rejection of rat renal allograftsEvaluation of microvascular reactivity with laser Doppler flowmetry in chronic kidney diseaseEmerging role of epoxyeicosatrienoic acids in coronary vascular function.Endogenous inhibitors of nitric oxide and preeclampsia: a review.ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction.Impact of Continuous Erythropoietin Receptor Activator on Selected Biomarkers of Cardiovascular Disease and Left Ventricle Structure and Function in Chronic Kidney Disease.Nitric oxide and L-arginine metabolism in a devascularized porcine model of acute liver failure.Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease.Endothelial function in patients with familial Mediterranean fever-related amyloidosis and association with cardiovascular events.Metabolomic Profiling of Arginine Metabolome Links Altered Methylation to Chronic Kidney Disease Accelerated Atherosclerosis.Comprehensive assessment of nephrotoxicity of intravenously administered sodium-oleate-coated ultra-small superparamagnetic iron oxide (USPIO) and titanium dioxide (TiO2) nanoparticles in rats.Relation between asymmetric dimethylarginine (ADMA) and hearing loss in patients with renal impairment.Asymmetrical dimethylarginine plasma clearance persists after acute total nephrectomy in rats.Concentrations of representative uraemic toxins in a healthy versus non-dialysis chronic kidney disease paediatric population.Accumulation of uraemic toxins is reflected only partially by estimated GFR in paediatric patients with chronic kidney disease.Contribution of whole blood to the control of plasma asymmetrical dimethylarginine.Asymmetric dimethyl-arginine and coronary artery calcification in young adults entering middle age: the CARDIA Study.Biological variation of asymmetric dimethylarginine and related arginine metabolites and analytical performance goals for their measurement in human plasma.ADMA correlates with portal pressure in patients with compensated cirrhosis.
P2860
Q27665385-07ED2CA6-EE65-4731-BB34-ADA799C939A2Q28488125-42653B08-02E3-45C6-8ADD-29F8EBB764B2Q33242325-9F857D0F-142C-416C-B226-6F2EC0B3A8A1Q33371562-08189A82-7F83-49A0-8129-A2159E18DBDEQ33847194-FC111CED-E9B2-4B19-9335-174608A78D53Q34426973-05A333B9-6CB4-402F-9372-C627E080A1B8Q35047495-00E16E41-1435-4B8C-A418-E5CF715121B8Q36458500-B5F13BF0-CECA-46D9-9136-2DBA43A27710Q36590924-5130673F-BD86-4BC9-9A9E-9F485F07B01FQ36677348-E51C3CC1-15D6-42E1-968A-AA0212B5111EQ36681249-7EC404B5-7E0B-4695-933C-AC33320B58CCQ37174684-8E1E1320-6AC4-4FE1-9B61-2971BC3B072AQ38853235-69B58CDC-A8F0-4DCC-9433-E605870F06F5Q40204455-111A8902-FE99-4574-95E9-85F635F02DB9Q41979223-E430623F-D4ED-413D-ACEE-79A305ECB966Q43465717-EB607AD7-23AA-4163-B146-B08C52E61180Q46313782-0A59AB55-6CCE-42D6-8DA7-01F8AD5989ECQ46661250-B720C87D-4138-48E5-99FA-E99F309ACB1DQ47676937-DB96A1BF-A985-48C4-98D8-6F14D688C675Q47676953-B2804EA7-55BF-4660-B408-2991DBFE783CQ50736531-61391F97-671D-4EA0-ADD7-3AE6546C0333Q51756269-C7014CE1-20F8-47E8-B141-B7D5EDD4C7DAQ53021614-4FBFD023-D490-40CD-B0D0-42710A0E3C25Q54312440-730E47F5-BEB7-425A-8309-D65D079E3771
P2860
Asymmetric dimethylarginine (ADMA): the silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Asymmetric dimethylarginine (A ...... cardiovascular risk molecule.
@ast
Asymmetric dimethylarginine (A ...... cardiovascular risk molecule.
@en
type
label
Asymmetric dimethylarginine (A ...... cardiovascular risk molecule.
@ast
Asymmetric dimethylarginine (A ...... cardiovascular risk molecule.
@en
prefLabel
Asymmetric dimethylarginine (A ...... cardiovascular risk molecule.
@ast
Asymmetric dimethylarginine (A ...... cardiovascular risk molecule.
@en
P2860
P1476
Asymmetric dimethylarginine (A ...... cardiovascular risk molecule.
@en
P2093
P2860
P356
10.1111/J.1365-2362.2005.01457.X
P577
2005-02-01T00:00:00Z